企業プロフィール
Arcus Biosciences 株価・ニュース・カタリスト
- ティッカー:
- RCUS
- 取引所:
- NYSE
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
25.23 USD (-2.32%)
終値
最終更新: 2026年10月1日
3.08B USD
時価総額
株価変動の要因
2026年10月1日 時点で RCUS は 2.32% 下落し、$25.23 で取引を終えました。現在のニュース監視期間内に同社の新しいニュースは確認されませんでした。
企業概要
Clinical-Stage Oncology and Immunology Company
Arcus Biosciences develops differentiated medicines for cancer and immune-mediated diseases. Its research model combines internally discovered molecules, biomarker-driven clinical development, and collaborations that can broaden the number and scale of combination studies.
Casdatifan Kidney Cancer Franchise
Casdatifan is an oral HIF-2α inhibitor being developed as a potential backbone therapy for clear-cell renal cell carcinoma. Arcus is studying the molecule as monotherapy and in combinations with zimberelimab, cabozantinib, and other agents across first-line, second-line, and later-line settings.
Quemliclustat in Pancreatic Cancer
Quemliclustat is a small-molecule CD73 inhibitor designed to reduce immunosuppressive adenosine in the tumor microenvironment. The program has advanced into the Phase 3 PRISM-1 study in metastatic pancreatic cancer in combination with chemotherapy.
Checkpoint and Combination Capabilities
Zimberelimab, an anti-PD-1 antibody, supports Arcus-controlled immuno-oncology combinations and may reduce dependence on externally sourced checkpoint inhibitors. The company also uses partnerships, including its alliance with Gilead, to fund and execute broad late-stage development programs.
Emerging Immunology Pipeline
Arcus is extending its discovery platform beyond oncology through AB102, an MRGPRX2-targeting antibody for mast-cell-driven diseases, and an oral TNF inhibitor. These programs add allergic and inflammatory disorders to a pipeline historically centered on solid tumors.
今後のカタリスト
- Multiple ARC-20 casdatifan datasets in renal cell carcinoma during the second half of 2026, including first-line combinations, second-line casdatifan plus cabozantinib, and late-line monotherapy follow-up.
- Initiation of the Phase 3 PEAK-20 casdatifan study by year-end 2026.
- Completion of enrollment in the Phase 3 PEAK-1 casdatifan study by year-end 2026.
- Phase 3 PRISM-1 results for quemliclustat in metastatic pancreatic cancer in the first half of 2027.
- Initial clinical proof-of-concept data for AB102 in mast-cell-driven disease around mid-2027.
最近のニュース
ニュースタイトルは機械翻訳です。詳細は英語の原文をご覧ください。
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。